Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Viscosupplementation consists of injection with hyaluronic acid which are directly injected into the joint with the aim of restoring the rheological properties in knee and hip. Hyaluronic acid is a naturally occurring substance found in synovial fluid surrounding the joints and acts as lubricant. The rising pool of Knee Arthritis, Hip Osteoarthritis patient population have less hyaluronic acid thereby externally viscosupplementation are provided to patient to reduce the pain and suffering caused. The growing healthcare spending for treatment across the Asia Pacific is expected to increase the demand for market.
The factors contributing in Asia Pacific viscosupplementation market growth are increasing incidence of knee osteoarthritis due to increasing obesity, injuries, fractures, growing number of sport injuries has led the demand for market to huge extent. Besides, changing lifestyle, hereditary, has significantly propel the growth thereby promoting the viscosupplementation market. Also, integration of proprietary technology has offer significant opportunities for market. Furthermore, rising old age population is the key factor accelerating the demand for the market.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the Asia Pacific viscosupplementation market. In addition, complete analysis of changes on the Asia Pacific viscosupplementation market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market.
The viscosupplementation market comprises of different market segment like product, hyaluronic acid type, application, end-user and country
By product, the viscosupplementation market includes key segment of single injection, three injection, and five injection. Three injection has dominated in the Asia Pacific viscosupplementation market owing to growing product requirement among patient which can help in reducing the pain, suffering and swelling caused by knee arthritis, hip osteoarthritis conditions. Besides, the product provided according to three doses which are given once in a week. Likewise, single injection is expected to witness rising demand in the region owing to growing adoption of the product for treatment with certain benefits.
The viscosupplementation market, includes different hyaluronic acid type like stabilized hyaluronic acid, standard hyaluronic acid. Stabilized hyaluronic acid is expected to gain major market share during the forecast period. The stabilized hyaluronic acid ideally have the properties like reducing pain and swelling which is expected to boost the demand for the market during the forecast period. Besides, standard hyaluronic acid is likely to witness growing demand in upcoming years owing to rising new innovation, research which is expected to contribute in the growth of market during the estimated time period.
The viscosupplementation market finds its major application in knee arthritis, hip osteoarthritis and others. Knee arthritis is expected to lead in the market attributing to the rising burden of knee arthritis in the region. Also, the region has growing number of sport injuries, fractures, trauma, hereditary which is expected to boost the demand for the market. Furthermore, the hip osteoarthritis has growing number of patient population majorly due to obesity, fractures, which has led the rising demand for the market. This features of segment is expected to propel the growth of market during the estimated time period.
The viscosupplementation market has different end user like hospitals, orthopedic clinics/ambulatory surgical centers (ascs). Hospitals is expected to gain major market in Asia Pacific for viscosupplementation. The rising patient inflow and growing injuries, growing geriatric population, knee arthritis, hip osteoarthritis patient has led the demand for segment to provide the treatment thereby viscosupplementation market finds its major opportunity in Asia Pacific region. Orthopedic clinics/ambulatory surgical centers (ascs) is expected to hold second position in the market during the estimated time period as the population in Asia Pacific.
Asia Pacific viscosupplementation market is studied for the following countries like China, India, Japan and Rest of APAC among others. China is projected to lead in the market during the estimated time period. The growing burden and prevalence of knee arthritis, hip osteoarthritis among others has significantly increased the demand for market. Furthermore, growing healthcare expenditure and adoption of viscosupplementation among population has propel the growth of market. However, India is expected to witness the growth at rapid pace during the forecast period. The increasing number of patient, and requirement for treatment like viscosupplementation has contributed in the growth of market to huge extent.
The key players in viscosupplementation market are Anika Therapeutics, Inc. , Aptissen SA , Bioventus, Singclean ,CROMA-PHARMA, Dr. Reddy's Laboratories, Ferring Pharmaceuticals, Fidia Pharma USA Inc , BioPolymer GmbH & Co. KG, Johnson & Johnson, LG Life Sciences, LABRHA International , Virchow biotech, Sun Phrama , Mylan, OrthogenRx , Roche, Ettsons , Sanofi Genzyme, Seikagaku Corporation, Smith & Nephew, Stellar Phamaceuticals Inc, Tecnofarma S.A., TRB Chemedica International, Wellchem Pharmaceuticals Pte Ltd., Zimmer Biomet
March 2021: Seikagaku Corporation announced a manufacturing and marketing approval in Japan for JOYCLU 30mg Intra-articular Injection, a Joint Function Improvement Agent, for the Indication of Osteoarthritis (Knee Joint and Hip Joint). The approval is based on the results of three Phase III clinical studies. The company demonstrated a statistically significant improvement in WOMAC pain scores over twelve weeks after the initial injection.
January 2019: Bioventus launched Durolane, single injection joint fluid osteoarthritis treatment in Malaysia and selected Athrotech as its exclusive distribution partner for market. Arthotech is beneficial for Bioventus as it continues to grow in Asia and expand the reach and Malaysia is the fourth market in Asia where Durolane is introduced.
May 2019: Lupin and Aptissen S.A announced a definitive distribution agreement under which Aptissen had granted the Lupin, exclusive rights to market, sell and distribute the current Aptissen’s product in Canada. This agreement gave immediate right to distribute Synolis VA for the treatment of Osteoarthritis in Canada. Synolis VA is the intra-articular injection product used to treat osteoarthritis.
October 2018: Sanofi Genzyme had announced the data from analyses of the Kevzara (sarilumab) Phase 3 clinical development program was presented at the 2018 ACR/ARHP Annual Meeting, which is being held in Chicago from October 19 to 24. In the mobility trial, patients with high IL-6 levels treated with Kevzara were more likely to demonstrated improvement in clinical signs and symptoms and had less joint damaged according to radiographic assessment versus those with high IL-6 levels treated with MTX alone.
The report analyses the Asia Pacific viscosupplementation market based on by product, hyaluronic acid type, application, end-user and country. By product, the viscosupplementation market includes key segment of single injection, three injection, and five injection. Three injection has dominated in the Asia Pacific viscosupplementation market. The viscosupplementation market, includes different hyaluronic acid type like stabilized hyaluronic acid, standard hyaluronic acid. Stabilized hyaluronic acid is expected to gain major market share during the forecast period. The viscosupplementation market finds its major application in knee arthritis, hip osteoarthritis and others. Knee arthritis is expected to lead in the market. The viscosupplementation market has different end user like hospitals, orthopedic clinics/ambulatory surgical centers (ascs). Hospitals is expected to gain major market in Asia Pacific for viscosupplementation. Asia Pacific viscosupplementation market is studied for the following countries like China, India, Japan and Rest of APAC among others.
Why to buy this report:
